AbCellera Biologics Inc. (ABCL) climbed to a new 52-week high of $5.97 on Wednesday, ending the regular session just below that mark at $5.96. Momentum continued after hours, with the stock rising another 11.58% to finish at $6.65, building on its earlier 18.49% gain. The move follows a series of recent developments that have drawn attention to the company's expanding immunology pipeline and clinical progress.
AbCellera, a biotechnology firm focused on antibody-based therapies, has been steadily advancing its portfolio, with several programs now entering human trials.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.